Antileukemic T-cell-mediated immune reactions: Limitations and perspectives for future therapies

Immunotherapy

Volumn 3, Issue 7, 2011, Pages 809-811

  Schmetzer, Helga Maria ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

acute myeloid leukemia; dendritic cell; immune escape; immunotherapy; T cell

Indexed keywords

ANTILEUKEMIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; DENDRITIC CELL; IMMUNITY; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TUMOR IMMUNITY;

CHEMOKINE CCL2; DENDRITIC CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; INTERLEUKIN-8; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 79960527416     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.75     Document Type: Review

References (13)

1. Kolb HJ, Schmid C, Barrett AJ et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103, 767-776 (2004).
2. Schmitt A, Hus I, Schmitt M. Dendritic cell vaccines for leukaemia patients. Expert Rev. Anticancer Ther. 7(3), 275-283 (2007).
3. Tuyaerts S, Joeri LA, Corthals J et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56(10), 1513-1537 (2007).
4. Schmetzer H. Dendritic cells as prognostic indicators or as immunotherapeutic tools to treat acute myeloid leukemia (AML) and high grade myelodysplasia (MDS).Review. Recent advances and Research Updates 9(1), 125-137 (2008) (invited publication, award as Eminent Scientist of the Year 2007).
5. Kremser A, Dreyssig J, Grabrucker C et al. Dendritic cells can be successfully generated from leukaemic blasts in individual patients wit AML or MDS: an evaluation of different methods. J. Immunother. 33, 185-199 (2010).
6. Smits EL, Lee C, Hardwick N et al. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol. Immunother. 60(6), 757-769 (2011).
7. Anguille S, Lion E, Smits E et al. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum. Vaccin. 7(5), 579-584 (2011).
8. Schmetzer H, Kremser A, Loibl J et al. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC ('DCleu') contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia 21, 1338-1341 (2007).
9. Grabrucker C, Liepert A, Dreyssig J et al. The quality and quantity of leukemia-derived dendritic cells (DC) from patients with acute myeloid leukaemia and myelodysplastic syndrom are a predictive factor for the lytic potential of DC-primed leukemia-specific T cells. J. Immunother. 33(5), 523-537 (2010).
10. Liepert A, Grabrucker C, Kremser A et al. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell. Immunol. 265, 23-30 (2010).
11. Schick J, Vogt V, Zerwes M et al. Antileukaemic T-cell responses after dendritic cell stimulation can be predicted by compositions of regulatory T-cell subpopulations, especially with respect to regulatoty central memory and regulatory CD8 cells. Bone Marrow Transplant. 46(Suppl. 1), Abstract 1048 (2011).
12. Vogt V, Schick J, Zerwes M et al. Antileukaemic T-cell responses after DC-stimulation can be predicted by composition of T-cell subpopulations especially with respect to nai¨ve, central memory and non-naive T-cells. Bone Marrow Transplant. 46(Suppl. 1), Abstract 1047 (2011).
13. Fischbacher D, Merle M, Liepert A et al. The composition and quality of leukemia-derived dendritic cells, T-cells and cellular microenvironment is predictive for the antileukemic T-cell cytotoxic reactions of DC-primed T-cells and the response to therapy. Bone Marrow Transplant. 43(Suppl. 1), Abstract 905 (2009).